TY - JOUR
T1 - High-sensitive cardiac troponin I (hs-cTnI) values in patients with stable cardiovascular disease
T2 - An initial foray
AU - Schulz, Olaf
AU - Reinicke, Markus
AU - Berghoefer, Gunnar H.
AU - Bensch, Ricarda
AU - Kraemer, Jochen
AU - Schimke, Ingolf
AU - Jaffe, Allan S.
PY - 2010/6
Y1 - 2010/6
N2 - Background: How to use the information from novel high sensitivity troponin assays in stable cardiac patients is unclear. Preliminary data from randomized controlled trial analyses suggest it helps with risk stratification. We investigated the determinants, diagnostic impact and prognostic value of a novel high-sensitive cardiac troponin I (hs-cTnI) assay in patients with stable cardiac disease. Methods: hs-cTnI was measured with a pre-commercial assay in 222 outpatients after clinical testing before cardiac catheterization. Mean follow-up was 1103. ±. 299 days. Results: hs-cTnI was detectable in all patients (median (interquartile range) 6.20 (4.85;8.25) ng/l). Creatinine (p<. 0.001), systolic wall stress (p= 0.004), the presence of myocardial impairment (p= 0.049) and coronary artery stenosis ≥70% (p= 0.050) were predictors of hs-cTnI concentration.hs-cTnI values could not distinguish elevations due to myocardial abnormalities from those related to coronary artery abnormalities. Patients with elevations above the 99th percentile had a higher rate of hospitalizations but otherwise prognosis was not predicted robustly by hs-cTnI values. Conclusion: Stable cardiovascular patients have detectable hs-cTnI concentrations irrespective of their underlying disease. In this heterogeneous group of patients with diverse etiologies for cardiac disease, values were not helpful in distinguishing the etiology of the elevations or in predicting prognosis.
AB - Background: How to use the information from novel high sensitivity troponin assays in stable cardiac patients is unclear. Preliminary data from randomized controlled trial analyses suggest it helps with risk stratification. We investigated the determinants, diagnostic impact and prognostic value of a novel high-sensitive cardiac troponin I (hs-cTnI) assay in patients with stable cardiac disease. Methods: hs-cTnI was measured with a pre-commercial assay in 222 outpatients after clinical testing before cardiac catheterization. Mean follow-up was 1103. ±. 299 days. Results: hs-cTnI was detectable in all patients (median (interquartile range) 6.20 (4.85;8.25) ng/l). Creatinine (p<. 0.001), systolic wall stress (p= 0.004), the presence of myocardial impairment (p= 0.049) and coronary artery stenosis ≥70% (p= 0.050) were predictors of hs-cTnI concentration.hs-cTnI values could not distinguish elevations due to myocardial abnormalities from those related to coronary artery abnormalities. Patients with elevations above the 99th percentile had a higher rate of hospitalizations but otherwise prognosis was not predicted robustly by hs-cTnI values. Conclusion: Stable cardiovascular patients have detectable hs-cTnI concentrations irrespective of their underlying disease. In this heterogeneous group of patients with diverse etiologies for cardiac disease, values were not helpful in distinguishing the etiology of the elevations or in predicting prognosis.
KW - Chronic cardiac disease
KW - High sensitivity troponin
UR - http://www.scopus.com/inward/record.url?scp=77956460987&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956460987&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2010.02.066
DO - 10.1016/j.cca.2010.02.066
M3 - Article
C2 - 20188720
AN - SCOPUS:77956460987
SN - 0009-8981
VL - 411
SP - 812
EP - 817
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
IS - 11-12
ER -